Vision loss arising from retinal diseases often follows a progressive course and can significantly complicate an individual's daily life. The primary goal in today's treatment of retinal diseases is to preserve existing visual functions, slow the progression of the disease, and ensure the visual capacity is maintained for as long as possible. MagnoVision, one of the new generation technologies developed in this direction, is considered a supportive approach in retinal diseases.
What is MagnoVision Treatment?
MagnoVision treatment can be defined as a supportive application based on electromagnetic stimulation targeting retina and optic nerve cells. The main aim of this approach is to support the metabolic activity of cells located in the retina layer involved in the vision process, helping to preserve existing visual functions.
MagnoVision is not a surgical procedure and is applied without requiring invasive intervention. The treatment process can be planned as a result of an expert physician's evaluation, considering the patient’s existing eye disease, vision level, and general health status.
Which Eye Diseases can MagnoVision be Evaluated for?
MagnoVision treatment is not a suitable method for every eye disease. However, in some progressive diseases arising from the retina and optic nerve, it might be considered a supportive approach following a physician's evaluation.
Retinitis Pigmentosa
Retinitis pigmentosa is a group of diseases with a genetic transition, progressing with the damage over time of photoreceptor cells in the retina layer. It usually starts with night vision difficulty and can lead to a narrowing of the visual field in later stages. Since the disease follows a progressive course, supportive methods aimed at preserving existing visual functions and slowing the progression of the disease can be considered in treatment approaches.
Retinal Diseases Progressing with Night Blindness
Night blindness is a condition characterized by reduced visual ability in low light conditions. It is often associated with a decrease in the light sensitivity of retinal cells. Night blindness can be a disease on its own or an early symptom of different retinal diseases. In such cases, approaches aimed at supporting retinal functions can be included in the evaluation by the physician.
Progressive Retinal Degenerations
Retinal degenerations are diseases that progress with structural and functional disorders in the retina layer. Over time, loss of function of photoreceptor cells can affect visual acuity and the visual field. In these diseases, the aim is to reduce the rate of vision loss and to ensure the preservation of existing visual capacity for as long as possible.
Retina-Related Visual Function Disorders
In some diseases, even if the retina structure is not completely lost, functional loss at the cellular level can develop. This situation may present itself as a reduction in visual quality, decreased contrast sensitivity, or weakness in visual perception. In such functional disorders, approaches aimed at supporting the metabolic activity of retinal cells can be considered following a physician's evaluation.
Optic Nerve and Retina-Related Functional Losses
In certain conditions affecting the transmission process between the optic nerve and the retina, the transmission of visual signals to the brain may not occur adequately. In such functional losses, treatment planning can be done following a detailed neuro-ophthalmological evaluation, and supportive applications can be considered as part of an integrated approach.
How is MagnoVision Treatment Applied?
MagnoVision treatment is a non-invasive application that does not require surgical intervention or injection. The treatment process is planned by an expert physician following a detailed eye examination and necessary retinal evaluations. During the application, a special device providing electromagnetic stimulation is used, and this stimulation can be applied in a controlled manner targeting retinal and optic nerve cells.
The treatment is generally conducted on an outpatient basis, prioritizing patient comfort during application. As this process does not cause pain, patients can return to their daily lives shortly. The number of sessions and the duration of the application may vary depending on the type and stage of the disease and the patient's response to treatment.
Throughout the treatment process, patients are scheduled for regular follow-up examinations, and changes in visual functions are monitored. MagnoVision is not evaluated as a stand-alone treatment method but as part of an integrated eye health approach and can be planned along with other supportive methods when necessary.
What Supportive Applications are Implemented in MagnoVision Treatment?
MagnoVision treatment is not applied as a standalone method in retinal diseases; instead, it is considered part of a holistic approach planned by considering the patient's current condition, the stage of the disease, and visual functions. In this process, different supportive applications may also be included in the treatment plan if deemed appropriate by the physician for some patients.
Among these supportive approaches, PRP (Platelet Rich Plasma) and stem cell-based applications may be included. However, these methods are not standard for every patient, nor do they replace MagnoVision treatment. The decision of suitability can be determined by detailed eye examination, tests, and expert physician evaluation.
PRP and stem cell applications are considered approaches aimed at biologically supporting the retina and surrounding tissues. It is planned specifically for the patient regarding which patients, at what stage, and for what purpose these applications can be used. The main goal during the treatment process is to preserve existing visual functions and closely monitor the course of the disease.
What is the Post-Treatment Process of MagnoVision?
After the treatment, patients can return to their daily lives. It does not require a special recovery process post-application. However, MagnoVision should not be evaluated as a standalone treatment method but as a part of an integrated eye health approach. Follow-up examinations suggested by the physician form an important part of the treatment process.
Frequently Asked Questions
How many sessions does MagnoVision treatment last?
The number of sessions and the duration of the treatment can vary based on the patient's existing eye disease and the treatment plan created by the physician. Therefore, there is no standard number of sessions.
Is MagnoVision suitable for every retinal patient?
No. MagnoVision treatment may not be suitable for every retinal patient. Suitability should be determined following a detailed eye examination and evaluation by an expert physician.
Is MagnoVision treatment a surgery?
No. MagnoVision treatment is not a surgery requiring surgical incision, injection, or sutures. It is planned as a non-invasive application and is not considered an alternative to surgical procedures.
Is MagnoVision treatment painful?
MagnoVision treatment is not a surgical procedure and generally does not cause pain. Patient comfort is prioritized during the application, and treatment can be carried out on an outpatient basis. Most patients do not experience noticeable discomfort during or after the application.
